TURKOVA, Barbora, Jan TUZIL, Barbora PILNACKOVA, Helena DOLEZALOVA, Daniela STROSOVA, Vit PETRU, Ester SEBEROVA and Tomáš DOLEŽAL. Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic. IMMUNOTHERAPY. London: FUTURE MEDICINE LTD, 2022, vol. 14, No 14, p. 1109-1120. ISSN 1750-743X. Available from: https://dx.doi.org/10.2217/imt-2022-0143.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic
Authors TURKOVA, Barbora (203 Czech Republic), Jan TUZIL (203 Czech Republic, guarantor), Barbora PILNACKOVA (203 Czech Republic), Helena DOLEZALOVA (203 Czech Republic), Daniela STROSOVA (203 Czech Republic), Vit PETRU (203 Czech Republic), Ester SEBEROVA (203 Czech Republic) and Tomáš DOLEŽAL (203 Czech Republic, belonging to the institution).
Edition IMMUNOTHERAPY, London, FUTURE MEDICINE LTD, 2022, 1750-743X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.800
RIV identification code RIV/00216224:14110/22:00128329
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2217/imt-2022-0143
UT WoS 000853009100001
Keywords in English allergy; costs; economics; effectiveness; immunotherapy; pollen; rhinitis; rhinoconjunctivis; savings; subcutaneous
Tags 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 27/1/2023 13:49.
Abstract
Plain language summary Hay fever has become more frequent over the years, and allergen immunotherapy (AIT) remains the only treatment able to reduce both symptoms and the root cause of this condition. However, it is not clear whether the benefits outweigh the price of the therapy. In this study, we observed patients in the common practice and described the effectiveness, safety and costs of injected AIT for pollen-induced hay fever. Of 471 new AIT users, 317 completed three courses of treatment in 3 consecutive years. Symptoms improved in 96% of them; no serious adverse reactions were reported. The cost of symptom-relieving medication decreased by 49% and the cost of unscheduled physician visits decreased by 73%. Except for costs related to AIT administration, total healthcare costs decreased by 54% compared with the years before AIT. In clinical practice, injected AIT is an effective treatment which generates savings on other medication and unscheduled physician consultations. Tweetable abstract In Czech clinical practice, subcutaneous allergen immunotherapy is an effective treatment for allergic rhinoconjunctivitis, generating savings on symptomatic medication and unscheduled physician consultations. Background: The prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. Methods: In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis. Results: Of 471 new AIT users, 317 completed three courses of treatment, and symptoms improved in 96%; no serious adverse reactions were reported. The cost of symptomatic medication decreased by 49% and the cost of unscheduled specialist visits decreased by 73%. Except for AIT administration, total healthcare costs decreased by 54% compared with the baseline pollen season without AIT. Conclusion: In clinical practice, subcutaneous AIT is an effective treatment generating savings on symptomatic medication and unscheduled consultations.
PrintDisplayed: 22/8/2024 03:34